| Literature DB >> 33791979 |
Chang Shao1,2, Wenjie Lu3, Haiping Hao4,5, Hui Ye6.
Abstract
Cancer cells exhibit different metabolic patterns compared to their normal counterparts. Although the reprogrammed metabolism has been indicated as strong biomarkers of cancer initiation and progression, increasing evidences suggest that metabolic alteration tuned by oncogenic drivers contributes to the occurrence and development of cancers rather than just being a hallmark of cancer. With this notion, targeting cancer metabolism holds promise as a novel anticancer strategy and is embracing its renaissance during the past two decades. Herein we have summarized the most recent developments in omics technology, including both metabolomics and proteomics, and how the combined use of these analytical tools significantly impacts this field by comprehensively and systematically recording the metabolic changes in cancer and hence reveals potential therapeutic targets that function by modulating the disrupted metabolic pathways.Entities:
Keywords: Anticancer target discovery; Chemoproteomics; Metabolic biomarker; Metabolomics; Proteomics
Mesh:
Substances:
Year: 2021 PMID: 33791979 DOI: 10.1007/978-3-030-51652-9_9
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622